The primary objective is to develop a biobank, tissue microarrays (TMAs) and full face sections, which will be used to identify candidate/ novel biomarkers prognostic for disease relapse and predictive for endocrine and/or chemotherapy resistance.
The secondary objectives are:
* To validate emerging signatures/biomarkers identified.
* To develop new assays for the breast cancer clinic.
